Clinical Trial Update: Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Adults [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating the effectiveness of a bivalent RSV prefusion F protein-based vaccine to prevent RSV-related hospitalizations in adults; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV bivalent prefusion F protein-based vaccine (Bivalent respiratory syncytial virus prefusion F protein-based vaccine)

Snippet

Sponsor: Tor Biering-Sørensen | Conditions: RSV | Phase 4 | Status: RECRUITING